Since Tz and pertuzumab (Pz) is a well-tolerated and highly effective treatment in HER2+ BC, we also evaluate the effects of 1 μg/mL Tz, 1 μg/mL Pz, and their combination (Tz + Pz, 1:1 μg/mL) on SKBR3 cells’ motility for 72 h. Here, ERBB2 is linked to breast cancer.